New proteasome inhibitors in myeloma (Q38052079)

27 August 2017

title

New proteasome inhibitors in myeloma (English)

1 reference

27 August 2017

10

Paul G Richardson

1 reference

27 August 2017

9

Kenneth C Anderson

1 reference

27 August 2017

3

Jacob Laubach

1 reference

27 August 2017

5

Claire Fabre

1 reference

27 August 2017

2

Dharminder Chauhan

1 reference

27 August 2017

8

Teru Hideshima

1 reference

27 August 2017

Constantine S Mitsiades

series ordinal

7

object named as

Constantine Mitsiades

1 reference

27 August 2017

6

Michelle Maglio

1 reference

27 August 2017

Panisinee Lawasut

1

1 reference

27 August 2017

Catriona Hayes

series ordinal

4

1 reference

27 August 2017

publication date

1 December 2012

1 reference

Current hematologic malignancy reports

27 August 2017

published in

1 reference

27 August 2017

volume

7

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

258-266

1 reference

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Discovery and Development of Second-Generation Proteasome Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

The immunoproteasome as a target in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11899-012-0141-2

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

12 December 2020

Proteasome inhibition in the treatment of cancer

1 reference

12 December 2020

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

1 reference

12 December 2020

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

1 reference

12 December 2020

10.1007/S11899-012-0141-2

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1017617920

0 references

1 reference